glp-1 lean mass loss Potential Breakthrough to Preserve Muscle During GLP-1-Induced Weight Do GLP-1 medications really cause

Claims (4) Applications Claiming Priority (3) Related Parent Applications (2) Publications (2) Family ID=6331195 Family Applications (2) Family Applications Before (1) Country Status (8) Cited By (1) Families Citing this family (38) Citations (1) Family Cites Families (5) 1987 1987-07-09 DE DE19873722647 patent/DE3722647A1/en not_active Ceased 1988 1988-07-08 AU AU19944/88A patent/AU1994488A/en not_active Abandoned 1988-07-08 JP JP63505693A patent/JP2851289B2/en not_active Expired - Lifetime 1988-07-08 EP EP88905695A patent/EP0327612B1/en not_active Expired - Lifetime 1988-07-08 AT AT94108938T patent/ATE188968T1/en not_active IP Right Cessation 1988-07-08 EP EP94108938A patent/EP0655460B1/en not_active Expired - Lifetime 1988-07-08 AT AT88905695T patent/ATE121942T1/en not_active IP Right Cessation 1988-07-08 WO PCT/DE1988/000427 patent/WO1989000427A1/en not_active Ceased 1996 1996-07-22 LV LV960291A patent/LV5793B4/en unknown 1997 1997-06-05 HK HK74697A patent/HK74697A/en not_active IP Right Cessation 1998 1998-07-22 JP JP10206738A patent/JPH11106349A/en active Pending 1998-07-22 JP JP10206743A patent/JPH11147836A/en active Pending

Cagrilintide as a standalone drug does not appear to be pursuing separate FDA approval at this time, as Novo Nordisk is focusing on the combination product

Mike Doustdar , Novo Nordisk CEO and president Novo Nordisk CEO and President Mike Doustdar said, This agreement with Hims & Hers is a meaningful win for patients in the United States

, -1, , , 2

Nonetheless, a holistic evaluation is implied